AI Biotechnology LLC - 31 Mar 2026 Form 3 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Reporting relationship
10%+ Owner
Issuer ticker
OKUR
Reported as of
31 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
07 Apr 2026, 21:15:00 UTC
Prior SEC filing
02 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Alejandro Moreno for AI Biotechnology LLC

Key filing fact

AI Biotechnology LLC filed Form 3 for OnKure Therapeutics, Inc. (OKUR) on 07 Apr 2026.

Key facts

  • This page summarizes AI Biotechnology LLC's Form 3 filing for OnKure Therapeutics, Inc. (OKUR).
  • 0 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 07 Apr 2026, 21:15.

Change

  • Previous filing in this sequence was filed on 02 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (4)

CIK 0001942670 Primary reporting owner

AI Biotechnology LLC

Relationship
10%+ Owner
Address
C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK
Signature
/s/ Alejandro Moreno for AI Biotechnology LLC
Signature date
07 Apr 2026
CIK 0001391297

Access Industries Holdings LLC

Relationship
10%+ Owner
Address
C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK
Signature
/s/ Alejandro Moreno for Access Industries Holdings LLC
Signature date
07 Apr 2026
CIK 0001508226

ACCESS INDUSTRIES MANAGEMENT, LLC

Relationship
10%+ Owner
Address
C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK
Signature
/s/ Alejandro Moreno for Access Industries Management, LLC
Signature date
07 Apr 2026
CIK 0001326628

Blavatnik Len

Relationship
10%+ Owner
Address
C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK
Signature
/s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik
Signature date
07 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OKUR holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,998,332
Date
31 Mar 2026
Ownership
Direct
Footnotes
F2
OKUR holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,998,332
Date
31 Mar 2026
Ownership
Direct
Footnotes
F2
OKUR holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,998,332
Date
31 Mar 2026
Ownership
Direct
Footnotes
F2
OKUR holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,998,332
Date
31 Mar 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OKUR holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Mar 2026
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
5,640,222
Exercise price
$0.000100
Footnotes
F1, F2
OKUR holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Mar 2026
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
5,640,222
Exercise price
$0.000100
Footnotes
F1, F2
OKUR holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Mar 2026
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
5,640,222
Exercise price
$0.000100
Footnotes
F1, F2
OKUR holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
31 Mar 2026
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
5,640,222
Exercise price
$0.000100
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each whole pre-funded warrant entitles AI Biotechnology LLC ("AIB") to purchase one share of Class A Common Stock at an exercise price equal to $0.0001 per share, and may be exercised at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined herein). The pre-funded warrants are not exercisable to the extent that the aggregate number of Class A Common Stock beneficially owned by AIB immediately following such exercise would exceed 9.99% of the Class A Common Stock outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker").

Footnote F2

The securities reported are held directly by AIB and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC remarks

Exhibit List: Ex.24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .